Each year, the H2i community comes together to help our Level 2 and 3 companies prepare for applying to the Creative Destruction Lab. Our program involves 5 easy steps to strengthen your venture and shape you into a competitive CDL applicant.  

Program Details

Please note that this program is a closed program and only available to current H2i Level 2 and 3 client companies.

Key Dates for Spring 2024 Program

  1. Peer-to-Peer Information Session | Wednesday June 19th, 2:00 – 3:30 PM ET on Zoom
  2. Application Review – To take part, please submit the below form between Monday June 24 – Friday July 5.
  3. 1-on-1 Mentorship Meetings – To take place the week of July 15th.

Info Session:

This event is open to H2i client companies only. An invite will be sent to register for the Pre-Application Information Session to be held on Wednesday June 19th 2024, 2:00 – 3:30 PM ET on Zoom.  The panel will feature fellow H2i clients who have experience within the CDL program.

Following the 40-minute panel discussion chaired by H2i Director Paul Santerre, there will be a 30-minute Q&A.

Please note this information session is a closed event for H2i ventures only.

Meet the Panelists | More to be Announced!

Dr. Natalie Galant | CEO and Co-founder, Paradox Immunotherapeutics 

Dr. Natalie Galant is the CEO and co-founder of Paradox Immunotherapeutics, a pharmaceutical company dedicated to the creation of antibody therapies for the treatment of rare protein misfolding diseases, especially those characterized by amyloidosis, using a platform with a proven track record of success.  

Prior to this role, Natalie received her PhD from the University of Toronto’s Department of Medical Biophysics, where her PhD work helped lead to the development of a monoclonal antibody currently in FDA clinical trials for the treatment of cardiac amyloidosis. She is the recipient of numerous academic fellowships, awards (incl. winner of BIO 2023 Start-Up Stadium), and has co-authored several scientific publications in research areas ranging from chemical informatics and cryo-EM to immunotherapy drug development.  

Chris Bass | CEO & Co-Founder, InventoRR MD  

Harold Wodlinger | President, Wodlinger Consulting  

Harold Wodlinger is a consultant to the medical device industry.  He has more than forty years of experience in product development, operations, sales, and management, and a proven track record in strategic planning, business development, and due diligence.    

Harold is Chairman of the Board of Exact Imaging (prostate cancer imaging) and Chairman of Swiftsure Medical (oral care for ventilated patients).  Five previous board positions resulted in successful exits.  He is a mentor with the Creative Destruction Lab and with the Health Technology Exchange, a member of the strategic advisory board of iGan Partners and was formerly an Adjunct Professor at the University of Toronto where he taught a graduate course in medical product development.  He has performed more than thirty due diligence studies for venture capitalist and angel investors.  He directed product development at ViTAA Medical (aortic aneurysm diagnosis and therapy), SoundBite Medical Solutions (device to penetrate chronic total occlusions in cardiac and peripheral arteries), CardioInsight Technologies (non-invasive cardiac mapping), and MyndTec Inc (stroke rehabilitation).  

Prior to becoming a consultant, Harold founded Biomedical Instrumentation Inc, a company that developed and manufactured equipment in the field of cardiac electrophysiology.  The company sold more than 500 systems in 20 countries and was acquired by the Quinton Instrument Company of Seattle. 

Harold holds a BASc in Electrical Engineering and a PhD in Biomedical Engineering from the University of Toronto. 

Zaid Atto | CEO, Xpan Inc

Apply for 2024 Pre-Application Mentorship

Applications for H2i’s Pre-Application Mentorship will be open from June 24th to July 5th.


Please visit the CDL website for more information, or email info.h2i@utoronto.ca.

DISCLAIMER: H2i and all affiliated client companies do not guarantee successful intake into the CDL program. All opinions expressed herein on this webpage and at program events are speakers’ own and do not reflect CDL nor H2i as a wholeH2i level 2 and 3 companies engage with this program at their own discretion and understand that H2i is not responsible for application outcomes.